Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Moderate to Severe Ulcerative Colitis – Phase II Induction
CTR20182462Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in autoimmune colitis, sponsored by Hengrui Therapeutics. Started Jan 2019; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20182462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182462.